

Mahdi Barzegar, MD

Date of Birth: January 27, 1994

Phone (home): +98 1142232283

Phone (cell): +989117800592

Email address: barzegar_mahdi73@yahoo.com

EDUCATION

Doctorate of medicine (MD); Isfahan University of Medical Sciences, Isfahan, Iran

2012-2019

Completed with GPA: 3.28 (out of 4)

POSITIONS AND PROFESSIONAL EXPERIENCES

Isfahan Neurosciences Research Center; Isfahan University of Medical Sciences, Iran

2013-present

Position: Co-head of student research team on neuro-immunological disorders: Multiple Sclerosis and Neuromyelitis optica spectrum disorders

General Practitioner; Private practice, Iran

2019-present

Students' Research Committee, Isfahan University of Medical Sciences, Iran

2013-2019

Positions: Board member, Deputy of Education Unit, Head of Research Unit, Chief Financial Officer, Reviewer of the Research Council, and Member

Responsibilities: Contribution to policy making, strategic planning, and administrative activities of the research center, as well as designing and holding new research training workshops

2nd Annual Isfahan Student Research Day; Isfahan University of Medical Sciences, Iran

2015

Position: Congress Chairperson

Research Day is an annual forum where all students from Isfahan University of Medical Sciences present their scholarly work and research and learn about the investigative activities of their peers.

Responsibilities: Conducting meeting; reviewing the agenda for the congress, scheduling conference calls

AWARDS

Best researcher student of research center

Isfahan Neurosciences research center, Iran (2014)

Prominent member of Young Counselors' Council of Medical School

Isfahan University of Medical Sciences, Iran (2017)

Accepted educational proposal in Education Festival

Isfahan University of Medical Sciences, Iran (2018)

PUBLICATIONS

PubMed publications

1. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
Published: July 2021 in Neurology: Neuroimmunology & Neuroinflammation
Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH.
2. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Published: May 2020 in Neurology: Neuroimmunology & Neuroinflammation
Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, Shaygannejad V.
3. Early predictors of conversion to secondary progressive multiple sclerosis.
Published: September 2021 in Multiple Sclerosis and Related Disorders
Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, Mirmosayyeb O, Shaygannejad V.
4. Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: November 2020 in Journal of Clinical Medicine
Barzegar M, Sadeghi Bahmani D, Mirmosayyeb O, Azarbajegani R, Afshari-Safavi A, Vaheb S, Nehzat N, Dana A, Shaygannejad V, Motl RW, Brand S.

5. Frequency of comorbidities in Neuromyelitis Optica spectrum disorder.
Published: February 2021 in Multiple Sclerosis and Related Disorders
Barzegar M, Mirmosayyeb O, Nehzat N, Vaheb S, Shaygannejad V, Asgari N
6. COVID-19 Susceptibility and Outcomes among Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Review and Meta-Analysis.
Published: November 2021 in Multiple Sclerosis and Related Disorders
Barzegar M, Mirmosayyeb O, Ebrahimi N, Bagherieh S, Afshari-Safavi A, Hosseinabadi AM, Shaygannejad V, Asgari N.
7. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
Published: July 2021 in Multiple Sclerosis and Related Disorders
Barzegar M, Vaheb S, Mirmosayyeb O, Afshari-Safavi A, Nehzat N, Shaygannejad V.
8. Assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis
Published: December 2020 in Psychology, Health & Medicine
Barzegar M, Allahdadian S, Mirmosayyeb O, Azarbayejani R, Badihian S, Nehzat N, Daryanavardi S, Barzegar S, Shaygannejad V
9. Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls
Published: July 2019 in Multiple Sclerosis and Related Disorders
Barzegar M, D Sadeghi Bahmani, Nehzat N, Kiani M, Hashemi N, Mirmosayyeb O, Serge Brand, Shaygannejad V
10. Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran
Published: May 2018 in Multiple Sclerosis and Related Disorders
Barzegar M, Badihian S, Mirmosayyeb O, Ashtari F, Jamadi M, Emami S, Jahani L, Safavi A, Shaygannejad V
11. Characteristics of COVID-19 disease in multiple sclerosis patients
Published: October 2021 in Multiple Sclerosis and Related Disorders
Barzegar M, Mirmosayyeb O, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, Vosoughi R.
12. Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis.
Published: February 2021 in Dysphagia
Barzegar M, Mirmosayyeb O, Rezaei M, Bjørklund G, Nehzat N, Afshari-Safavi A, Shaygannejad V.
13. Sociodemographic and illness-related indicators to predict the status of neuromyelitis optica spectrum disorder (NMOSD) five years after disease onset
Published: January 2022 in Journal of Clinical Medicine
Sadeghi Bahmani D, **Barzegar M**, Mirmosayyeb O, , Vaheb S, Nehzat N, Shaygannejad V, Brand S

14. Optical Coherence Tomography in Neuromyelitis Optica spectrum disorder and Multiple Sclerosis: A population-based study.
Published: January 2021 in Multiple Sclerosis and Related Disorders
Ashtari F, Ataei A, Kafieh R, Khodabandeh Z, **Barzegar M**, Raei M, Dehghani A, Mansurian M.
15. Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS).
Published: January 2021 in Multiple Sclerosis International
Mirmosayyeb O, **Barzegar M**, Afshari-Safavi A, Nehzat N, Heidari A, Emami P, Shaygannejad V
16. Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.
Published: December 2020 in Autoimmunity Reviews
Mirmosayyeb O, Shaygannejad V, **Barzegar M**, Nehzat N, Gajarzadeh M.
17. The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis.
Published: September 2020 in Journal of Clinical Neuroscience
Mirmosayyeb O, **Barzegar M**, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M.
18. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.
Published: May 2020 in Journal of Clinical Medicine
Mirmosayyeb O, Brand S, **Barzegar M**, Afshari-Safavi A, Nehzat N, Shaygannejad V, Sadeghi Bahmani D.
19. Screening neuromyelitis optica patients for COVID-19 infection
Published: November 2020 in Autoimmunity Reviews
Mirmosayyeb O, Vaheb S, **Barzegar M**, Shaygannejad V, Bonavita S, Ghajarzadeh M
20. Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
Published: July 2021 in Neurology Research International
Nehzat N, Mirmosayyeb O, **Barzegar M**, Vosoughi R, Fazeli E, Shaygannejad V.
21. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
Published: June 2021 in Neurological Sciences
Moghadasi AN, Mirmosayyeb O, **Barzegar M**, Sahraian MA, Ghajarzadeh M.
22. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Published: August 2020 in Multiple Sclerosis and Related Disorders
Ghajarzadeh M, Mirmosayyeb O, **Barzegar M**, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH.

23. Omega 3 Supplementation Can Regulate Inflammatory States in Gas Station Workers: A Double-Blind Placebo-Controlled Clinical Trial.
Published: May 2020 in Journal of Interferon & Cytokine Research
Barkhordari S, Mirmosayyeb O, Mansourian M, Hosseininasab F, Ramezani S, **Barzegar M**, Amin MM, Poursafa P, Esmaeil N, Kelishadi R.
24. Incidence, Prevalence, and Characteristics of Heart Failure Among Patients with Multiple Sclerosis; A Systematic Review and Meta-Analysis
Published: August 2022 in Multiple Sclerosis and Related Disorders
Bagherieh S, Ghoshouni H, Bostan F, Afshari-Safavi A, Badihian S, **Barzegar M**, Shaygannejad V, Mirmosayyeb O
25. An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
Published: June 2018 in Journal of neuroimmunology.
Ashtari F, Esmaeil N, Mansourian M, Poursafa P, Mirmosayyeb O, **Barzegar M**, Pourghesari H.
26. Serum leptin levels in Iranian patients with Parkinson's disease.
Published: April 2018 in Iranian journal of neurology.
Salari M, **Barzegar M***, Etemadifar M, Mirmosayyeb O.
27. The interplay of multiple sclerosis and menstrual cycle: Which one affects the other one?
Published: February 2018 in Multiple Sclerosis and Related Disorders.
Mirmosayyeb O, Badihian S, Manouchehri N, Kahid Basiri A, **Barzegar M**, Esmaeil N, Fayyazi E, Shaygannejad V.
28. Prevalence of Trigeminal Neuralgia in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Published: January 2021 in Multiple Sclerosis and Related Disorders.
Houshia S, Tavallaeia MJ, **Barzegar M**, Afshari-Safavi A, Vaheb S, Mirmosayyeb O, Shaygannejad V.
29. Post COVID-19 Infection Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report-Based Systematic Review
Published: February 2022 in Multiple Sclerosis and Related Disorders.
Mirmosayyeb O, Ghaffary EM, Bagherieh S, **Barzegar M**, Dehghan MS, Shaygannejad V
30. The Serum Level of Midkine in Patients with Multiple Sclerosis and Neuromyelitis Optica.
Published: March 2021 in Basic and Clinical Neuroscience.
Moayednia M, Dehghani L, Safi A, Shaygannejad V, Sohrabi K, Rezvani M, Akrami MR, Soghrati M, Aboutalebi MM, **Barzegar M**.
31. Bell's palsy after Sputnik V COVID-19 (Gam-COVID-Vac) vaccination

Published: August 2022 in Clinical Case Reports
Mirmosayyeb O, Barzegar M, Rezaei M, Baharlouie N, Shaygannejad V

Journal publications

1. Serum Bilirubin Level Changes in Multiple Sclerosis Patients.
Published: January 2018 in Caspian Journal of Neurological Sciences.
Barzegar M, Shaygannejad V, Mirmosayyeb O, Valipour S, Akbari R, Vesal S, Ashtar F, Dehghani L, Mohammadi A, Esmail N.
2. Anti-myelin Oligodendrocyte Glycoprotein in Aquaporin-4 Negative Neuromyelitis Optica Spectrum Disorder.
Published: January 2021 in Caspian Journal of Neurological Sciences.
Shaygannejad V, **Barzegar M**, Manouchehri N, Esmail N, Nehzat N, Badihian S, Ashtari F, Mirmosayyeb O.
3. Ischemic Strokes in a Young Woman With Manifestations of Multiple Sclerosis.
Published: October 2018 in Caspian Journal of Neurological Sciences.
Janghorbani M, **Barzegar M**, Mirmosayyeb O, Shaygannejad V.
4. Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
Published: April 2020 in Current Journal of Neurology.
Mirmosayyeb O, **Barzegar M**, Nehzat N, Najdaghi S, Ansari B, Shaygannejad V
5. Comparison of Bladder Dysfunction and Urinary Symptoms Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
Published: August 2019 in Caspian Journal of Neurological Sciences.
Nasr Esfahani F, Manouchehri N, Nehzat N, Mirmosayyeb O, **Barzegar M**, Shaygannejad V.
6. Post-treatment Guillain-Barre Syndrome in a Patient with Brucellosis; A Case Report.
Published: May 2019 in Internal Medicine and Medical Investigation Journal.
Manouchheri N, Mirmosayyeb O, Ghasemi M, Badihian S, Shaygannejad V, **Barzegar M**.
7. Tumefactive Brain Lesions in Patients with Neuromyelitis Optica Spectrum Disorder.
Published: May 2019 in Caspian Journal of Neurological Sciences.
Manouchehri N, Nehzat N, Mirmosayyeb O, Shaygannejad V, Barzegar M.
8. Medical Students' Clerkship Exposures to Expected Clinical Skills and Comparison with the Specified Minimums.
Published: December 2018 in Iranian Journal of Medical Education.
Yaghini O, Yamani N, Daryazadeh S, Barzegar M, Sadeghi A.

Manuscripts under review

1. Risk of SARS-CoV-2 reinfection in patients with multiple sclerosis vs. the general population: a population-based study

Barzegar M, Manteghinejad A, Mirmosayyeb O, Sindarreh S, Haghjooy Javanmard S, Vahid Shaygannejad V, Nasirian M

2. Association of disease-modifying therapies with COVID-19 susceptibility and severity in patients with multiple sclerosis: A systematic review and network meta-analysis
Barzegar M, Bagherieh S, Houshi S, Hashemi MS, Pishgahi G, Afshari-Safavi A, Mirmosayyeb O, Shaygannejad V, Zabeti A.
3. Relation between Helicobacter pylori infection and Neuromyelitis optica spectrum disorder with negative anti-aquaporin 4 antibody
Barzegar M, Nouri H, Mirmosayyeb O, Motedayyen H, Nehzat N, Shaygannejad V
4. Prevalence of dysphagia in patients with multiple sclerosis: a systematic review and meta-analysis
Mirmosayyeb O, Ebrahimi N, Shekarian A, Bagherieh S, Afshari-Safavi A, Shaygannejad V, **Barzegar M***.
5. Sexual Dysfunction in Women with Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis
Mirmosayyeb O, **Barzegar M**, Nafari A, Hosseinabadi AM, Malekzadeh A, Ghasemi M, Barzegar S, Shaygannejad V.
6. Association between comorbidities and health-related quality of life in patients with multiple sclerosis
Mirmosayyeb O, **Barzegar M**, Rezaei M, Afshari-Safavi A, Falahatian M, Houshi S, Nasim Nehzat N, Shaygannejad V
7. Olfactory Dysfunction in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis
Mirmosayyeb O, Ebrahimi N, **Barzegar M**, Afshari-Safavi A, Bagherieh S, Shaygannejad

LOCAL PUBLICATIONS (BOOKS AND LOCAL PRESENTATIONS)

1. Successful live with Multiple sclerosis
Published: 2020 in Vajhiran publication
Authors: **Barzegar M**, Mirmosayyeb O, Shaygannejad V, Nehzat N, Fayyazi E, Lotfi F, Vaheb S, Bathaie R.
2. Successful live with NMOSD
Published: 2019 in Vajhiran publication.
Authors: **Barzegar M**, Mirmosayyeb O, Shaygannejad V, Nehzat N, Afshar F, Molavi Z, Mohamadi S.
3. Multiple sclerosis for physicians
Published: 2018 in Vajhiran publication.

Authors: **Barzegar M**, Mirmosayyeb O, Shaygannejad V, Eskandari N, Esmaeil N, Dehbashi M, Dehghani L, Sadrameli M, Fayyazi M, Maljaie MB, Nazari F.

4. An overview on research unit of Students' Research Committee
Published: October 2017 in Golbang Journal.
Authors: **Barzegar M**
5. An overview on financial office of Students' Research Committee
Published: October 2016 in Golbang Journal.
Authors: **Barzegar M**

CONGRESS PRESENTATIONS

Oral presentations

1. Serum Leptin levels in Iranian patients with Parkinson's disease
25th congress of Iranian Neurology and Electrophysiology, Tehran, Iran (2018).
2. Clinical characteristics, course and prognosis in early-onset MS and late-onset MS: Comparison with adult-onset forms
26th congress of Iranian Neurology and Electrophysiology, Tehran, Iran (2019).
3. Prognosis of multiple sclerosis and its possible influential factors
28th congress of Iranian Neurology and Electrophysiology, Tehran, Iran (2021).

Conference abstracts

1. Fall frequency and risk factors in patients with neuromyelitis optica spectrum disorder.
ACTRIMS-ECTRIMS 2020.
Authors: **Barzegar M**, Mirmosayyeb O, Azarbajehani R, Brand S, Afshari-Safavi A, Shaygannejad V, Sadeghi Bahmani D.
2. Relationship between comorbidities and health-related quality of life in patients with multiple sclerosis.
ACTRIMS-ECTRIMS 2020.
Authors: **M Barzegar**, O Mirmosayyeb, M Rezaei, A Afshari-Safavi, V Shaygannejad.
3. Clinical characteristics of neuromyelitis optica spectrum disorder and multiple sclerosis in Iranian pediatric patients.
ACTRIMS-ECTRIMS 2020
Authors: **Barzegar M**, Mirmosayyeb O, Shaygannejad V.

4. Relation between helicobacter pylori infection and double seronegative neuromyelitis optica spectrum disorder.
ACTRIMS-ECTRIMS 2020.
Authors: **Barzegar M**, Nouri H, Bjorklund G, Mirmosayyeb O, Motedayyen H, Shaygannejad V.
5. Progression to Secondary Progressive Multiple Sclerosis and its Early Risk Factors: A Population-based Study.
AAN Annual Meeting 2020.
Authors: **Barzegar M**, Shaygannejad V, Mirmosayyeb O, Afshari-Safavi A.
6. Restless leg syndrome in multiple sclerosis and neuromyelitis optica spectrum disorder: A case-control study in Iran.
MENACTRIMS 2018.
Authors: **Barzegar M**, Shaygannejad V, Azarbayejani R.
7. Evaluation of sleep quality and risk assessment of obstructive sleep apnea among MS patients.
ECTRIMS 2017.
Authors: Manouchehri N, Mirmosayyeb O, Hashemi N, Kiani M, **Barzegar M**, Allahdadian S, Shaygannejad V.
8. Association of Serum Bilirubin Levels With Relapsing Remitting Multiple Sclerosis.
PACTRIMS 2016.
Authors: **Barzegar M**, Esmail N, Mirmosayyeb O, Vesal S, Valipour S, Akbari R, Shaygannejad V
9. Ischemic Strokes in a Young Woman With Manifestations of Multiple Sclerosis: Can Ischemic Stroke Mimic Multiple Sclerosis?
PACTRIMS 2016.
Authors: V Shaygannejad, M Janghorbani, **M Barzegar**, O Mirmosayyeb.

TRAINING COURSES

Good clinical practice

National Institute for Medical Research Development (NIMAD), Iran (2019)

Systematic review and meta-analysis

Universal Scientific Education and Research Network (USERN), Iran (2019)

Research Methodology Workshop, principals of research methodology

Isfahan University of Medical Sciences, Iran (2013)

Medline Workshop, How to search in scientific databases

Isfahan University of Medical Sciences, Iran (2013)

SPSS workshop

Isfahan University of Medical Sciences, Iran (2013)

TEACHING EXPERIENCES

Lecturer at school of mentor-assisted research training (SMART)

Isfahan University of Medical Sciences, Iran (2017-2018)

Lecture at Isfahan Research Accelerator Program

Isfahan University of Medical Sciences, Iran (2018)

Lecturer of Research Methodology Workshop

Isfahan University of Medical Sciences, Iran (2016-2019)

Lecture at Scientific Writing Workshop

Isfahan University of Medical Sciences, Iran (2018)

Lecture at How to submit a journal article manuscript

Isfahan University of Medical Sciences, Iran (2018-2019)

AD-HOC REVIEWER FOR THE FOLLOWING JOURNALS:

- Multiple Sclerosis and related Disorders
- Journal of the Neurological Sciences
- Neurology and Therapy
- Scientific Reports
- ImmunoTargets and Therapy
- Neuropsychiatric Disease and Treatment
- Frontiers in Neurology